Extended therapeutic effect ocular implant treatments
First Claim
Patent Images
6. The method of 1, wherein the implant has a weight between about 1 μ
- g and about 100 mg.
1 Assignment
0 Petitions
Accused Products
Abstract
Methods for treating ocular conditions by inserting an implant comprising an active agent into an ocular site of a patient thereby obtaining an amelioration of a symptom of the ocular condition (i.e. a therapeutic effect) for an extended period of time during which a therapeutic amount or a detectable amount of the active agent is not present at the ocular site.
-
Citations
29 Claims
-
6. The method of 1, wherein the implant has a weight between about 1 μ
- g and about 100 mg.
-
18. A method for treating a chronic ocular condition, the method comprising the steps of:
-
(a) inserting an implant into an ocular site of a patient with an ocular condition, the implant comprising (i) an active agent, and (ii) a carrier associated with the active agent;
(b) releasing substantially all of the active agent from the implant;
(c) obtaining an improvement in the ocular condition at a time when a therapeutic amount of the active agent is not present at the ocular site, and;
(d) maintaining the improvement in the ocular condition for an extended period of time during which a therapeutic amount of the active agent is not present at the ocular site.
-
-
19. A method for treating an inflammatory posterior ocular condition, the method comprising the steps of:
-
(a) inserting a biodegradable implant into a posterior ocular site of a patient with an inflammatory posterior ocular condition, the biodegradable implant comprising (i) an anti-inflammatory active agent mixed with (ii) a biodegradable polymer;
(b) releasing substantially all of the anti-inflammatory active agent from the biodegradable implant;
(c) obtaining an improvement in the inflammatory posterior ocular condition at a time when a therapeutic amount of the anti-inflammatory active agent is not present at the posterior ocular site, and;
(d) maintaining the improvement in the inflammatory ocular condition for an extended period of time during which a therapeutic amount of the anti-inflammatory active agent is not present at the posterior ocular site. - View Dependent Claims (20)
-
-
21. A method for treating persistent macular edema, the method comprising the steps of:
-
(a) inserting a biodegradable implant deep into the vitreous of a patient with persistent macular edema, the biodegradable implant comprising (i) dexamethasone mixed with (ii) a bioerodible PLGA co-polymer;
(b) releasing all of the dexamethasone from the biodegradable implant;
(c) obtaining an improvement in the persistent macular edema at a time when a therapeutic amount of the dexamethasone is not present in the vitreous, and;
(d) maintaining the improvement in the persistent macular edema for an extended period of time during which a therapeutic amount of the dexamethasone is not present in the vitreous. - View Dependent Claims (1, 2, 3, 4, 5, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 22, 23, 24, 25, 26)
-
-
24-1. The method of claim 21, wherein the obtaining step comprises obtaining an improvement in the visual acuity of the patient.
-
27. A method for improving the visual acuity of a patient with persistent macular edema, the method comprising the steps of:
-
(a) inserting a biodegradable implant into the vitreous of a patient with persistent macular edema by placing the biodegradable implant about 2 mm to about 6 mm anterior of the macular, the biodegradable implant comprising (i) about 700 μ
g dexamethasone mixed with (ii) a bioerodible PLGA co-polymer;
(b) releasing the 700 μ
g of dexamethasone from the biodegradable implant within about 30 days to about 40 days after the inserting step;
(c) obtaining an improvement in the visual acuity of the patient with the persistent macular edema at a time within about 30 days and 180 days after the inserting step during which time a therapeutic amount of the dexamethasone is not present in the vitreous, and;
(d) maintaining the improvement in the visual acuity of the patient with the persistent macular edema for about 30 days to about 150 days after the obtaining step during a time a therapeutic amount of the dexamethasone is not present in the vitreous.
-
-
28. A method for treating an ocular condition, the method comprising the steps of:
-
(a) inserting an implant into the vitreous cavity of a patient with an ocular condition, the implant comprising (i) a steroid, and (ii) a carrier associated with the steroid;
(b) releasing substantially all of the steroid from the implant, and;
(c) obtaining an improvement in the ocular condition with no increase in intraocular pressure above about 25 mm Hg.
-
-
29. A method for treating an ocular condition, the method comprising the steps of:
-
(a) inserting an implant into the vitreous cavity of a patient with an ocular condition, the implant comprising (i) a steroid, and (ii) a carrier associated with the steroid;
(b) releasing substantially all of the steroid from the implant, and;
(c) obtaining an improvement in the ocular condition with no occurrence of an ocular cataract in the patient.
-
Specification